An initiative of the World Peptide Foundation · Every experience matters
Loading the peptide directory…
Desmopressin — Peptide Scientific Intelligence
Scientific intelligence record
Experience 2.0
Vasopressin analog
Desmopressin
Desmopressin is a synthetic analog of arginine vasopressin modified by deamination at position 1 and D-arginine at position 8. It preferentially activates renal V2 receptors, increasing collecting-duct water reabsorption through aquaporin-2 trafficking; V2-mediated endothelial release of von Willebrand factor and factor VIII underlies selected haemostatic uses. Clinical effects and risks differ materially by indication, dose, route, formulation, renal function, fluid intake, age, and concomitant medicines.
Record status
Traceability partial
Last meaningful update: 9/9/2026
Evidence searched through:
Not recorded
Assessment updated:
9/9/2026
Last human review:
No accountable human review represented
Governed reviewed evidence
25
Governed records, not an efficacy score or total literature count.
Evidence boundary
0 / 25
Claim-linked support versus recorded evidence.
Research gaps
1
Unresolved questions remain visible.
Human experience · separate evidence stream
No community pattern is displayed yet
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
Research chronology
1987 · study · Temporal status not established
1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial.
Annals of internal medicine
1995 · study · Temporal status not established
Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study.
The Journal of urology
1999 · study · Temporal status not established
Desmopressin in the treatment of nocturnal polyuria in the male.
BJU international
1999 · study · Temporal status not established
Desmopressin resistant enuresis: pathogenetic and therapeutic considerations.
The Journal of urology
Connections
Follow the scientific relationships
Connections appear only when they are represented by the project’s underlying records.
Open 12 represented connections ↓Close represented connections ↑
institution
BJU international
represented evidence source
institution
Lower urinary tract symptoms
represented evidence source
institution
Journal of pediatric urology
represented evidence source
institution
The Journal of urology
Traceability
Follow the record back to its source
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Claim → Evidence
Incomplete
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Incomplete links: claim-to-evidence
Inspect 25 source paths ↓Close source paths ↑
Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.
Observational archive
What contributors reported
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Reviewed jurisdictional records
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Read the scientific record with its boundaries intact
The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Desmopressin evidence · ranking key
How evidence is ranked
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
A
Practice-defining evidence
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
D
Signal-generating evidence
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
Tier and confidence answer different questions
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
peptide explorer
Structural visualization and provenance
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Duplicate-safe scientific sources under accountable human review. Identified or pending records do not contribute as approved evidence.
0
Insufficient
WPF-EMM-1.0
Identified sources
6
Governed reviewed
0
Evidence approved for publication
0
Audit view
Evidence integrity map
Human and preclinical evidence remain separate. Source identity, claim-to-source traceability, review dates, conflicts, limitations, and unknowns stay visible rather than being collapsed into one score.
4 unresolved signals
Human evidence
0
Preclinical evidence
0
Human experience
Below display gate
Observations never become clinical evidence.
• Hyponatremia, water intoxication, seizures, and other serious consequences can occur, especially with excess fluid intake, renal impairment, older age, interacting medicines, inappropriate route or dose, or illness affecting fluid and electrolyte balance. Intranasal, oral, sublingual, and injectable products are not dose-equivalent. Evidence for particular haemostatic and perioperative uses is mixed and context-dependent. Current product labeling controls sodium monitoring, fluid restriction, contraindications, warnings, and approved indications.
• The presence of published evidence does not by itself establish safety, efficacy, causation or clinical benefit.
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓Close records ↑
2020Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.
This study assessed the efficacy and safety of desmopressin orally disintegrating tablets (ODTs) in Japanese males (50 and 25 μg) and females (25 μg) with nocturia due to nocturnal polyuria (NP).
Authors
Osamu Yamaguchi, Kristian V Juul, Ali Falahati, Toru Yoshimura, Futoshi Imura, Mikiya Kitamura
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.
To investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in men.
Authors
A Mattiasson, P Abrams, P Van Kerrebroeck, S Walter, J Weiss
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
The risk of death from spontaneous intracerebral haemorrhage is increased for people taking antiplatelet drugs.
Authors
Michael J R Desborough, Rustam Al-Shahi Salman, Simon J Stanworth, Diane Havard, Lisa J Woodhouse, Jennifer Craig, Kailash Krishnan, Paul M Brennan, Robert A Dineen, Tim J Coats, Trish Hepburn, Philip M Bath
Source
The Lancet. Neurology
DOI
10.1016/s1474-4422(23)00157-6
PubMed
37353276
1999Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin in the treatment of nocturnal polyuria in the male.
To assess whether desmopressin (1-desamino 8-d-arginine vasopressin) is safe and effective in the treatment of nocturnal polyuria in elderly men.
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Randomized comparison of long-term desmopressin and alarm treatment for bedwetting.
To compare the efficacy of long-term primary nocturnal enuresis (PNE) treatment using desmopressin versus enuresis alarm.
Authors
Jonathan Evans, Birgitta Malmsten, Alison Maddocks, Harbans Singh Popli, Henri Lottmann, UK study group
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Evidence against a synergistic effect of desmopressin with conditioning in the treatment of nocturnal enuresis.
To test the hypothesis that desmopressin facilitates acquisition of continence, we aimed to establish whether, in children with nocturnal enuresis who are desmopressin nonresponders, adjunct desmopressin increases the rate of sustained continence after treatment with a conditioning alarm.
Authors
Susie Gibb, Terry Nolan, Mike South, Lea Noad, Giles Bates, Suzanna Vidmar
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin usage in elective cardiac surgery.
Desmopressin acetate (DDAVP) has been implicated as a promising agent to reduce blood loss in patients undergoing cardiopulmonary bypass.
Authors
E Ozkisacik, F Islamoğlu, H Posacioğlu, T Yağdi, S Başarir, S B Omay, M Ozbaran, S Büket
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin resistant enuresis: pathogenetic and therapeutic considerations.
We tested the role of the bladder in the pathogenesis of desmopressin resistant enuresis by evaluating the influence of urine production on the timing of the enuretic event and the response to anticholinergic medication.
Authors
T Nevéus, G Läckgren, T Tuvemo, U Olsson, A Stenberg
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study.
To determine if urine osmolality parameters can predict whether children with primary monosymptomatic nocturnal enuresis will respond to desmopressin, we conducted a prospective, double-blind, placebo-controlled study in 96 children 8 to 14 years old.
Authors
H G Rushton, A B Belman, M Zaontz, S J Skoog, S Sihelnik
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial.
To evaluate the effect of 1-desamino-8-D-arginine vasopressin (desmopressin) on blood loss in surgery, we conducted a randomized, double-blind trial of the drug in 35 patients with normal hemostatic function who were having spinal fusion with Harrington rod instrumentation.
Authors
N L Kobrinsky, R M Letts, L R Patel, E D Israels, R C Monson, N Schwetz, M S Cheang
Source
Annals of internal medicine
DOI
10.7326/0003-4819-107-4-446
PubMed
2010Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients.
Desmopressin decreases bleeding time in uremic patients.
Authors
Hyun Kee Lee, Yoon Ji Kim, Jin Uk Jeong, Jung Sik Park, Hyun Sook Chi, Soon Bae Kim
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.
Persons with mild hemophilia A (HA) may use intranasal desmopressin prior to sports participation.
Authors
Riten Kumar, Amy L Dunn, Jane E Schneiderman, Anne Gonzales, Vanessa Bouskill, Pamela Widener, Joseph Stanek, Fred G Pluthero, Amanda Waller, Cristina Tarango, Sanjay Ahuja, Bryce A Kerlin
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.
For a new formulation of a drug, only pharmacokinetic bioequivalence with the original formulation has to be demonstrated in healthy, young adults.
Authors
Robin Michelet, Lien Dossche, Charlotte Van Herzeele, Jan Van Bocxlaer, An Vermeulen, Johan Vande Walle, SAFE-PEDRUG consortium
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial.
Previous studies showed that desmopressin decreases post-operative blood loss in patients undergoing cardiac surgery.
Authors
E Bignami, M Cattaneo, G Crescenzi, M Ranucci, F Guarracino, C Cariello, R Baldassarri, G Isgrò, E Baryshnikova, G Fano, A Franco, C Gerli
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Side effects of desmopressin in patients with bleeding disorders.
Desmopressin is frequently used in patients with bleeding disorders because of its prohaemostatic effects.
Authors
S C M Stoof, M H Cnossen, M P M de Maat, F W G Leebeek, M J H A Kruip
Source
Haemophilia : the official journal of the World Federation of Hemophilia
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin effectiveness in renal colic pain management: Systematic review and meta-analysis.
This meta-analysis of trials was conducted to evaluate the impact of desmopressin on renal colic pain relief in comparison to more typically used medications (opioids and nonsteroidal anti-inflammatory drugs [NSAIDs]).
Authors
Mohammad Jalili, Pouya Entezari, Amin Doosti-Irani, Rasoul Masoomi, Hadi Mirfazaelian
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy and safety of desmopressin in women with nocturia: a systematic review and meta-analysis of randomized controlled trials.
To evaluate the efficacy and safety of desmopressin treatment in women with nocturia.
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effect of desmopressin on bleeding outcomes after native renal biopsy: a systematic review and meta-analysis.
Percutaneous kidney biopsy is a key diagnostic tool in nephrology but carries a risk of post-procedure bleeding, with complications ranging from minor hematomas to life-threatening hemorrhages.
Authors
Ammar Yasser Ali, Rem Ehab Abdelkader, Rashad G Mohamed, Mohammed N Abdelaziz, Radwa M Abdelsattar, Ahmed R A Moustafa, Mohamed Rizk Elsayed, Bassant Barakat, Emad Samaan
Evidence strength A · 86/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review.
Dilutional hyponatremia is a serious adverse effect of desmopressin, a vasopressin analog that is widely prescribed to manage monosymptomatic enuresis.
Authors
Barbara Lucchini, Giacomo D Simonetti, Alessandro Ceschi, Sebastiano A G Lava, Pietro B Faré, Mario G Bianchetti
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials.
The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia.
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: A systematic review and meta-analysis.
Evidence on the efficacy of desmopressin in nocturia in patients with neurological diseases is still very limited except for multiple sclerosis (MS).
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis.
Desmopressin acetate was recommended for nocturia in benign prostatic hyperplasia (BPH) patients recently, but its effect and safety is still controversial.
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin for treating nocturia in men.
To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men.
Authors
Julia Han, Jae Hung Jung, Caitlin J Bakker, Mark H Ebell, Philipp Dahm
Evidence strength A · 86/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin to Prevent Rapid Sodium Correction in Severe Hyponatremia: A Systematic Review.
Hyponatremia is common among inpatients and is associated with severe adverse outcomes such as osmotic demyelination syndrome.
Authors
Thomas E MacMillan, Terence Tang, Rodrigo B Cavalcanti
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Desmopressin for nocturnal enuresis in children.
Enuresis (bedwetting) affects up to 20% of five-year-old children and 2% of adults.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
2001 · study · Temporal status not established
Desmopressin usage in elective cardiac surgery.
The Journal of cardiovascular surgery
2002 · study · Temporal status not established
Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.
BJU international
2004 · study · Temporal status not established
Evidence against a synergistic effect of desmopressin with conditioning in the treatment of nocturnal enuresis.
The Journal of pediatrics
2010 · study · Temporal status not established
Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients.
Nephron. Clinical practice
2011 · study · Temporal status not established
Randomized comparison of long-term desmopressin and alarm treatment for bedwetting.
Journal of pediatric urology
2012 · study · Temporal status not established
Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials.
International urology and nephrology
2013 · study · Temporal status not established
Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review.
Journal of pediatric urology
2015 · study · Temporal status not established
Desmopressin to Prevent Rapid Sodium Correction in Severe Hyponatremia: A Systematic Review.
The American journal of medicine
2016 · study · Temporal status not established
Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial.
Acta anaesthesiologica Scandinavica
2016 · study · Temporal status not established
Side effects of desmopressin in patients with bleeding disorders.
Haemophilia : the official journal of the World Federation of Hemophilia
2016 · study · Temporal status not established
Desmopressin effectiveness in renal colic pain management: Systematic review and meta-analysis.
The American journal of emergency medicine
2018 · study · Temporal status not established
Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.
European journal of clinical pharmacology
2018 · study · Temporal status not established
Desmopressin for treating nocturia in men.
BJU international
2019 · study · Temporal status not established
Efficacy and safety of desmopressin in women with nocturia: a systematic review and meta-analysis of randomized controlled trials.
International urology and nephrology
2020 · study · Temporal status not established
Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.
Lower urinary tract symptoms
2022 · study · Temporal status not established
Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.
Blood
2022 · study · Temporal status not established
The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis.
Lower urinary tract symptoms
2023 · study · Temporal status not established
Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
The Lancet. Neurology
2024 · study · Temporal status not established
Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: A systematic review and meta-analysis.
Neurourology and urodynamics
2025 · study · Temporal status not established
Effect of desmopressin on bleeding outcomes after native renal biopsy: a systematic review and meta-analysis.
Scientific reports
2025 · study · Temporal status not established
Desmopressin for nocturnal enuresis in children.
The Cochrane database of systematic reviews
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States (FDA — DDAVP)
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States (FDA — DESMODA)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
What still needs investigation
Claim traceability
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
Researchers represented in the evidence record12 bibliographic identities · open to inspect
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
P Abrams
2 represented evidence records
Years represented: 1999, 2002
Publishing organizations appearing in records: BJU international
A A McConnell
1 represented evidence record
Years represented: 1999
Publishing organizations appearing in records: BJU international
A B Belman
1 represented evidence record
Years represented: 1995
Publishing organizations appearing in records: The Journal of urology
A Cannon
1 represented evidence record
Years represented: 1999
Publishing organizations appearing in records: BJU international
A Franco
1 represented evidence record
Years represented: 2016
Publishing organizations appearing in records: Acta anaesthesiologica Scandinavica
A Mattiasson
1 represented evidence record
Years represented: 2002
Publishing organizations appearing in records: BJU international
A Stenberg
1 represented evidence record
Years represented: 1999
Publishing organizations appearing in records: The Journal of urology
Afra Darvishi
1 represented evidence record
Years represented: 2024
Publishing organizations appearing in records: Neurourology and urodynamics
Ahmed R A Moustafa
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: Scientific reports
Alessandro Ceschi
1 represented evidence record
Years represented: 2013
Publishing organizations appearing in records: Journal of pediatric urology
Ali Falahati
1 represented evidence record
Years represented: 2020
Publishing organizations appearing in records: Lower urinary tract symptoms
Alison Maddocks
1 represented evidence record
Years represented: 2011
Publishing organizations appearing in records: Journal of pediatric urology
represented evidence source
institution
International urology and nephrology
represented evidence source
institution
The Lancet. Neurology
represented evidence source
institution
The Journal of pediatrics
represented evidence source
institution
The Journal of cardiovascular surgery
represented evidence source
institution
Annals of internal medicine
represented evidence source
institution
Nephron. Clinical practice
represented evidence source
institution
Blood
represented evidence source
institution
European journal of clinical pharmacology
represented evidence source
Claim: Not linked · Evidence: 67a91b25a05ceda4f0b9e93a563edb83
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial.
Claim: Not linked · Evidence: 878aebf0546c1582fba4cab7860af628
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.
Generated: 9/18/2026, 3:17:42 PM
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
Loading interactive preview…
Durable source IDs
6/6
Claim-to-source chain
Partial
Evidence searched through: Not recorded
Last accountable review: Not recorded
Inspect unresolved signals (4)
No governed reviewed scientific source is represented.
The last accountable evidence-review date is not recorded.
At least one claim-to-original-source traceability step is not represented.
The literature search-through date is not recorded.
These are documentary and scientific-review signals, not conclusions of harm, ineffectiveness, safety, or absence of research.
Human relevance0
Study design0
Evidence breadth0
Consistency0
Governance quality0
Uncertainty resolution0
Why this rating
No governed reviewed scientific evidence is available.
Source-level review states (6)
identifiedother
Desmopressin and bleeding risk in high-risk native kidney biopsy: updated meta-analysis of RCTs and observational studies.
This maturity index describes evidence-base development and governance. It is not a probability of efficacy, safety, truth, medical advice, or regulatory approval. Read the methodology.